CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
Clinical safety rating: caution
No significant drug interactions Topical use only excessive use can lead to hypercalcemia.
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
| Metabolism | Calcipotriene undergoes hepatic metabolism primarily via cytochrome P450 (CYP) enzymes, including CYP24A1. Betamethasone dipropionate is metabolized in the liver via CYP3A4. |
| Excretion | Calcipotriene: renal elimination of metabolites; betamethasone dipropionate: primarily renal (70%) and biliary/fecal (30%) as metabolites. |
| Half-life | Calcipotriene: 12-24 hours; betamethasone dipropionate: 4-6 hours (parent), 3-5 hours (active metabolite betamethasone 17-propionate). |
| Protein binding | Calcipotriene: ~94% bound to plasma proteins; betamethasone dipropionate: ~64% bound (predominantly albumin). |
| Volume of Distribution | Calcipotriene: >1 L/kg (extensive tissue distribution); betamethasone dipropionate: not well characterized, likely large due to lipophilicity. |
| Bioavailability | Topical: minimal systemic absorption (<1% for calcipotriene, ~10-15% for betamethasone dipropionate via inflamed skin). |
| Onset of Action | Topical: clinical improvement within 2 weeks; maximum effect by 4-8 weeks. |
| Duration of Action | Topical: effects persist for several weeks after discontinuation; rebound may occur if stopped abruptly. |
| Molecular Weight | Calcipotriene: 412.6 Da; Betamethasone dipropionate: 504.6 Da |
Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 mL/day. Do not use under occlusive dressings.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No specific dose adjustment required for renal impairment. Use with caution in severe renal impairment due to potential for systemic absorption. |
| Liver impairment | No specific dose adjustment required for hepatic impairment. Use with caution in severe hepatic impairment due to potential for systemic corticosteroid effects. |
| Pediatric use | Safety and efficacy in children <12 years have not been established. For children ≥12 years, apply once daily to affected areas, limit use to <30 g/week, and avoid prolonged use. |
| Geriatric use | No specific dose adjustment required, but use with caution due to increased risk of skin atrophy and systemic effects. Avoid prolonged use and apply to limited areas. |
| 1st trimester | Topical corticosteroids are generally avoided in first trimester unless benefit outweighs risk. Calcipotriene is a vitamin D analog; systemic absorption minimal with topical use, but no well-controlled studies. Use only if clearly needed. |
| 2nd trimester | Limited data; topical application likely low risk but caution advised. Avoid prolonged use on large areas or under occlusion. |
| 3rd trimester | Similar to second trimester. Avoid excessive amounts on large body surface areas to minimize systemic absorption. |
Clinical note
No significant drug interactions Topical use only excessive use can lead to hypercalcemia.
| FDA category | Animal |
| Placental transfer | Betamethasone dipropionate crosses placenta; calcipotriene has limited data but likely minimal due to low systemic absorption. Both are teratogenic in animal studies at high doses, but clinical significance with topical use is unknown. |
■ FDA Black Box Warning
None.
| Common Effects | Skin irritation |
| Serious Effects |
Known hypersensitivity to calcipotriene or betamethasone dipropionateDermatological infections (viral, fungal, bacterial) at treatment siteSkin atrophy, perioral dermatitis, rosaceaPatients with known disorders of calcium metabolism (for calcipotriene component)
| Precautions | Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Local adverse reactions may include skin atrophy, striae, telangiectasias, burning, pruritus, folliculitis, and allergic contact dermatitis., May cause hypercalcemia and hypercalciuria due to calcipotriene component; monitor serum and urine calcium levels in patients with renal impairment or high doses., Avoid use on face, groin, axillae, or intertriginous areas due to increased risk of adverse effects., Not recommended for long-term continuous use due to potential for skin atrophy and systemic effects. |
Loading safety data…
| Breastfeeding | Not recommended for use on breasts prior to nursing; avoid application to large areas or prolonged use. Systemic absorption is minimal with topical use, but risk of infant exposure cannot be ruled out. Consider risk-benefit. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show increased risk of cleft palate and fetal growth restriction. In humans, first-trimester use of potent corticosteroids is associated with a small increased risk of oral clefts (OR 1.5). Second/third trimester: Prolonged use may cause fetal adrenal suppression and low birth weight. Avoid application to large areas (>30% BSA) or under occlusion. |
| Fetal Monitoring | Monitor fetal growth via ultrasound if used extensively (potential for low birth weight). Assess for maternal adrenal suppression if prolonged use on large areas. In neonates exposed to significant corticosteroids: observe for transient adrenal insufficiency. |
| Fertility Effects | No known effects on fertility from topical use. Systemic corticosteroids may impair ovulation (not relevant for topical route). |
| Food/Dietary | No significant food interactions. No dietary restrictions necessary for this topical medication. |
| Clinical Pearls | Apply only to psoriatic plaques, not to normal skin or flexures. Maximum weekly dose: 100g. Avoid occlusion. Use with caution on face, genitals, and intertriginous areas due to risk of corticosteroid atrophy. Discontinue if hypersensitivity develops. Monitor for hypercalcemia if used on extensive areas. Not recommended for use in children under 18 years. |
| Patient Advice | For external use only. · Apply once daily to psoriatic lesions only, avoiding unaffected skin. · Do not use more than 100 grams per week. · Do not cover with bandages or tight dressings. · Wash hands after application unless treating hands. · Avoid contact with eyes, mouth, and mucous membranes. · Do not use on face, armpits, or groin unless directed. · Inform your healthcare professional if you experience burning, itching, or skin thinning. · Use only on children under 18 if specifically prescribed. · Do not use for more than 4 weeks without medical evaluation. |